La Jolla Pharmaceutical Company (LJPC) Receives Daily Media Sentiment Score of 0.24

La Jolla Pharmaceutical Company (LJPC) Receives Daily Media Sentiment Score of 0.24

Here are some of the news articles that may have effected Alpha One Sentiment Analysis’s analysis:

News stories about La Jolla Pharmaceutical Company (NASDAQ:LJPC) have been trending somewhat positive this week, Alpha One Sentiment reports. The research firm, a division of Accern, rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. La Jolla Pharmaceutical Company earned a media sentiment score of 0.24 on Alpha One’s scale. Alpha One also assigned media stories about the biopharmaceutical company an impact score of 75 out of 100, indicating that recent news coverage is likely to have an impact on the company’s share price in the next several days.

A number of research firms recently issued reports on LJPC. Chardan Capital set a $34.00 price objective on shares of La Jolla Pharmaceutical Company and gave the stock a “buy” rating in a research report on Monday, May 22nd. Cowen and Company reiterated an “outperform” rating and set a $55.00 price objective (up from $40.00) on shares of La Jolla Pharmaceutical Company in a research report on Tuesday, February 28th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $57.00 price objective on shares of La Jolla Pharmaceutical Company in a research report on Monday, May 22nd. JPMorgan Chase & Co. reiterated a “buy” rating and set a $40.00 price objective (up from $27.00) on shares of La Jolla Pharmaceutical Company in a research report on Tuesday, February 28th. Finally, Zacks Investment Research cut shares of La Jolla Pharmaceutical Company from a “hold” rating to a “sell” rating in a research report on Tuesday, February 28th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $41.17.

La Jolla Pharmaceutical Company (LJPC) traded down 0.62% during midday trading on Tuesday, reaching $28.84. 287,609 shares of the company’s stock were exchanged. The stock’s market cap is $638.03 million. La Jolla Pharmaceutical Company has a 12 month low of $14.63 and a 12 month high of $39.28. The firm has a 50 day moving average of $28.55 and a 200-day moving average of $24.56.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.08. La Jolla Pharmaceutical Company had a negative net margin of 6,921.47% and a negative return on equity of 66.51%. On average, equities research analysts predict that La Jolla Pharmaceutical Company will post ($4.89) earnings per share for the current year.

In other news, Director Kevin C. Tang bought 149,254 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were bought at an average cost of $33.50 per share, with a total value of $5,000,009.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George F. Tidmarsh bought 3,000 shares of the firm’s stock in a transaction that occurred on Friday, March 3rd. The stock was purchased at an average cost of $34.17 per share, for a total transaction of $102,510.00. Following the completion of the purchase, the chief executive officer now owns 1,353,086 shares of the company’s stock, valued at $46,234,948.62. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 154,354 shares of company stock worth $5,175,174. 26.43% of the stock is owned by insiders.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:LJPC”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment